Fig. 2
Citrullinated vimentin is associated with good and poor EULAR response at 3/6 months in RA patients with available ACPA status.
Fig. 2 | The Pharmacogenomics Journal
Citrullinated vimentin is associated with good and poor EULAR response at 3/6 months in RA patients with available ACPA status.
